<DOC>
	<DOC>NCT01495156</DOC>
	<brief_summary>The proposed pilot study is a placebo-controlled, parallel group, randomized clinical trial comparing two treatment strategies in adolescents with mania and prominent psychotic features. One group will receive a second generation antipsychotic (SGA) and placebo and the other will receive a SGA and lithium. The primary double-blind phase of the study will last 8 weeks, followed by a 24-week extension-phase.</brief_summary>
	<brief_title>Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania</brief_title>
	<detailed_description />
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Males and females, 1218 years old, inpatients or outpatients meet DSMIV criteria for Bipolar I disorder manic or mixed episode psychotic symptoms present Exclusion criteria: current serious homicidal/suicidal ideation prior nonresponse or intolerance to an adequate trial of lithium prior nonresponse or intolerance to adequate trials of both aripiprazole and risperidone any unstable medical condition or medical contraindication to treatment with lithium, aripiprazole or risperidone inability or unwillingness to discontinue concomitant medication that interferes with the pharmacokinetics of either lithium, aripiprazole, or risperidone seizure disorder pregnant or, if sexually active, not using birth control, such as oral contraceptives, two barrier methods, longacting depot preparations or an intrauterine device Full Scale IQ less than 70 meets criteria for a DSMIV diagnosis of substanceinduced mood disorder or mood disorder due to a general medical condition.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>